Researcher
Eleonora Leucci
- Disciplines:Morphological sciences, Oncology
Affiliations
- Laboratory for RNA Cancer Biology (Division)
Responsible
From1 Jan 2018 → Today - Laboratory for RNA Cancer Biology (Division)
Member
From1 Jul 2018 → Today - Department of Oncology (Department)
Member
From1 Oct 2017 → 30 Jun 2018 - Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Member
From1 Sep 2012 → 30 Sep 2017
Projects
1 - 10 of 26
- Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometryFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- DIPITO: valorisation of deep immune profiling and novel immunotherapeutics for oncology.From1 Oct 2021 → TodayFunding: IOF - mandates
- Role of lncRNA in melanoma cell compartmentalization and therapy resistanceFrom20 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the added value of exosome-mediated dual targeting in the treatment of pancreatic ductal adenocarcinomaFrom15 May 2021 → 14 May 2023Funding: BOF - various
- Development of Patient Derived tumor Xenograft (PDXs) in vivo models to study new combination strategy in rectal cancerFrom11 Mar 2021 → 29 Sep 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Automated slide scanner for digitalizing histopathologyFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- Role of long non-coding RNA in tumour-associated macrophage polarizationFrom1 Oct 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Role of the rRNA modifications and lncRNA-derived micropeptides in melanoma translation rewiring and therapy resistanceFrom28 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Integration of complementary, high throughput single-cell omics with spatial resolution.From1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Role of MrT in cutaneous melanomaFrom1 Jan 2020 → 31 Dec 2023Funding: FWO research project
Publications
1 - 10 of 40
- A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma(2024)
Authors: Dennis Pedri, Ewout Landeloos, Yannick Van Herck, Katy Vandereyken, Thierry Voet, Wim Annaert, Diether Lambrechts, Veerle Boecxstaens, Joost van den Oord, Francesca Bosisio, et al.
- Humanized mouse models for anti-cancer therapy(2024)
Authors: Maria Francesca Baietti, Eleonora Leucci
Pages: 317 - 333 - Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy(2023)
Authors: Ali Talebi, Vincent de Laat, Xander Spotbeen, Jonas Dehairs, Ginevra Doglioni, David Nittner, Tania Roskams, Patrizia Agostinis, Oliver Bechter, Veerle Boecxstaens, et al.
- Hyperpolarized 13C-Pyruvate to Assess Response to Anti-PD1 Immune Checkpoint Inhibition in YUMMER 1.7 Melanoma Xenografts(2023)
Authors: Zorica Knezevic, Eleonora Leucci
- The LncRNA LENOX Interacts with RAP2C to Regulate Metabolism and Promote Resistance to MAPK Inhibition in Melanoma(2022)
Authors: Vicky Katopodi, Eleonora Leucci
Pages: 4555 - 4570 - The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma(2022)
Authors: Eleonora Leucci
- Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA(2022)
Authors: Maria Francesca Baietti, Maarten Albersen, Eleonora Leucci
- Establishment and Characterization of Advanced Penile Cancer Patient-derived Tumor Xenografts: Paving the Way for Personalized Treatments(2022)
Authors: Anne-Sophie Van Rompuy, Eduard Roussel, Lien Spans, Maria Francesca Baietti, Eleonora Leucci, Maarten Albersen
Pages: 1787 - 1794 - Editorial: Role of mitochondria-associated non-coding RNAs in intracellular communication(2022)
Authors: Eleonora Leucci
- LncRNAs in human cancers: signal from noise(2022)
Authors: Sara Adnane, Alessandro Marino, Eleonora Leucci
Pages: 565 - 573
Patents
1 - 6 of 6
- Uveal melanoma treatment (Inventor)
- Inhibition of a lncrna for treatment of melanoma (Inventor)
- Uveal melanoma treatment (Inventor)
- Inhibition of a lncrna for treatment of melanoma (Inventor)
- Inhibition of a lncrna for treatment of melanoma (Inventor)
- INHIBITION OF A LNCRNA FOR TREATMENT OF MELANOMA (Inventor)